Table 3.

Seroprevalence of AdHu5 and AdC68 neutralizing antibody in patients with different types of cancer.

	AdHu5	AdC68	P-value
Lung cancer	75.00% (60/80)	52.50% (42/80)	0.003
Laryngeal cancer	88.57% (31/35)	25.71% (9/35)	0.000
Oropharyngeal cancer	66.67% (6/9)	66.67% (6/9)	1.000
Esophageal cancer	67.11% (51/76)	32.89% (25/76)	0.000
Gastric cancer	77.50% (31/40)	75.00% (30/40)	0.793
Cervical carcinoma	54.17% (65/120)	26.67% (32/120)	0.000
Rectal cancer	65.00% (26/40)	70.00% (28/40)	0.633
Colon cancer	62.50% (25/40)	50.00% (20/40)	0.260